Ophthalmology

Mimetogen Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Mimetogen Pharmaceuticals Completes Enrollment of MIM-728 Phase 3 Trial for Tavilermide for Dry Eye Disease

Lead Product(s): Tavilermide

Therapeutic Area: Ophthalmology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

The MIM-728 trial is comparing the efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions to vehicle (placebo), each dosed two times a day (BID) for 12 weeks.

Immunovant

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401

Lead Product(s): IMVT-1401

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

Details:

65% mean reduction in total IgG was observed from baseline to end of treatment, with a pharmacodynamic (PD) response nearly identical to modeled predictions for dosing regimen tested in trial.

Opthea

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Opthea Completes Patient Dosing in Phase 2a DME Trial

Lead Product(s): OPT-302,Aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

Details:

Opthea completed patient dosing and all follow-up week 12 patient visits in the Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination with aflibercept.

Eyenovia

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Eyenovia, Inc. Announces Closing of Approximately $6.0 Million Private Placement

Lead Product(s): Pilocarpine

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: National Securities Corporation

Deal Size: $6.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement March 24, 2020

Details:

The offering are expected to be used for the MicroLine and MicroPine clinical studies, to advance MicroStat’s new drug application, and for working capital & general corporate purposes.

Leiden University Medical Center

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center

Lead Product(s): HORA-001

Therapeutic Area: Ophthalmology

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Horama SA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 18, 2020

Details:

HORAMA will receive an exclusive worldwide license to certain patent rights and know-how for the drug candidate (referenced as HORA-001).

IVERIC bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura

Lead Product(s): Avacincaptad Pegol

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

Company has decided to delay the initiation of enrollment of patients in the second pivotal clinical trial for Zimura® (avacincaptad pegol) for the treatment of geographic atrophy.

Graybug Vision

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102

Lead Product(s): Sunitinib Malate

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

A limited interim safety analysis performed in February 2020 supports Graybug’s intention to take the 1 mg dose forward for further exploration in clinical trials.

Ribomic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

RIBOMIC Enters License Agreement with AJU Pharma

Lead Product(s): RBM-007

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: AJU Pharma

Deal Size: $6.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 17, 2020

Details:

Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory.

Inceptua Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Luxembourg

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®

Lead Product(s): Ocriplasmin

Therapeutic Area: Ophthalmology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Oxurion

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 13, 2020

Details:

The Agreement with Inceptua will allow Oxurion to focus fully on further advancing its promising next-generation therapeutic pipeline of non-VEGF products for the treatment of diabetic eye disease.

Nicox SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial

Lead Product(s): NCX 470

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Ocumension Therapeutics

Deal Size: $165.0 million Upfront Cash: Undisclosed

Deal Type: Agreement March 11, 2020

Details:

Nicox will conduct both of its planned Phase 3 clinical trials, Mont Blanc and Denali, as multi-regional clinical trials in U.S. and China.

Find

Find Ophthalmology Clinical Drug Pipeline Developments & Deals

A collaboration with SCORR Marketing

Product Type

Development Status

Mimetogen Pharmaceuticals

Mimetogen Pharmaceuticals Completes Enrollment of MIM-728 Phase 3 Trial for Tavilermide for Dry Eye Disease

Immunovant

Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401

Opthea

Opthea Completes Patient Dosing in Phase 2a DME Trial

Eyenovia

Eyenovia, Inc. Announces Closing of Approximately $6.0 Million Private Placement

Leiden University Medical Center

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center

IVERIC bio

IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura

Graybug Vision

Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102

Ribomic

RIBOMIC Enters License Agreement with AJU Pharma

Inceptua Group

Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®

Nicox SA

Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial